Oxford Nanopore Technologies and Geneyx Announce the First Scalable Software Solution to Advance the Futu

The new platform is designed to enable the end-to-end analysis and clinical reporting of nanopore sequencing, empowering clinical labs, researchers and other users with an advanced, "one-click" solution

Oxford Nanopore Technologies plc (Oxford Nanopore), the company delivering a new generation of nanopore-based molecular sensing technology, and Geneyx, an AI platform for human genetic analysis and interpretation, are aiming to team up to develop the first scalable software solution for the end-to-end analysis and clinical reporting of nanopore sequencing data. The advanced platform will seamlessly empower clinical centres including hospitals, genetic labs and researchers with human whole-genome sequencing data and analysis.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230609005355/en/

The new software platform, which is anticipated to be commercially available following the completion of a pilot phase, is intended to advance the future clinical use of nanopore sequencing and will be designed to load, visualise and annotate nanopore sequencing data. Once available, it will be of immediate use in newborn screening and the research and characterisation of rare and undiagnosed diseases, providing "one-click" analysis of whole human sequencing data, including actionable genetic variants.